Dupilumab's Impact on Blood Parameters in Nasal Polyposis : 18-Month Follow-Up in Real Life
Copyright © 2023 Antonella Loperfido et al..
Background: Dupilumab represents the first approved biological for severe uncontrolled chronic rhinosinusitis with nasal polyps (CRSwNP).
Objective: Aim of this paper is to provide a multicentric real-life study about treatment with dupilumab for CRSwNP with a special focus on blood parameters and IgE, IgG, and IgA.
Method: A retrospective data collection was jointly conducted at the Otolaryngology departments of San Camillo Forlanini Hospital and University of Rome "La Sapienza" from December 2020 to January 2023.
Results: A total of 130 patients were included in the study. Monitoring our patients for 18 months, we observed a reduction in nasal polyposis and an improvement in symptoms and their impact on quality of life. Regarding blood tests, a transient increase in blood eosinophils was found in most cases. Total IgE showed a gradual decrease in values. IgG and IgA also showed a slight reduction of values, while remaining within normal ranges.
Conclusion: To the best of our knowledge, this is the first study to evaluate the impact of dupilumab on several blood parameters in patients receiving treatment for CRswNP. Further studies are needed to confirm our results and to understand the underlying immunological mechanisms.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:2023 |
|---|---|
| Enthalten in: |
Journal of immunology research - 2023(2023) vom: 15., Seite 4027701 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Loperfido, Antonella [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
37341-29-0 |
|---|
| Anmerkungen: |
Date Completed 26.09.2023 Date Revised 26.09.2023 published: Electronic-eCollection Citation Status MEDLINE |
|---|
| doi: |
10.1155/2023/4027701 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM362416745 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM362416745 | ||
| 003 | DE-627 | ||
| 005 | 20231226091207.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1155/2023/4027701 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1207.xml |
| 035 | |a (DE-627)NLM362416745 | ||
| 035 | |a (NLM)37745203 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Loperfido, Antonella |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Dupilumab's Impact on Blood Parameters in Nasal Polyposis |b 18-Month Follow-Up in Real Life |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 26.09.2023 | ||
| 500 | |a Date Revised 26.09.2023 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 Antonella Loperfido et al. | ||
| 520 | |a Background: Dupilumab represents the first approved biological for severe uncontrolled chronic rhinosinusitis with nasal polyps (CRSwNP) | ||
| 520 | |a Objective: Aim of this paper is to provide a multicentric real-life study about treatment with dupilumab for CRSwNP with a special focus on blood parameters and IgE, IgG, and IgA | ||
| 520 | |a Method: A retrospective data collection was jointly conducted at the Otolaryngology departments of San Camillo Forlanini Hospital and University of Rome "La Sapienza" from December 2020 to January 2023 | ||
| 520 | |a Results: A total of 130 patients were included in the study. Monitoring our patients for 18 months, we observed a reduction in nasal polyposis and an improvement in symptoms and their impact on quality of life. Regarding blood tests, a transient increase in blood eosinophils was found in most cases. Total IgE showed a gradual decrease in values. IgG and IgA also showed a slight reduction of values, while remaining within normal ranges | ||
| 520 | |a Conclusion: To the best of our knowledge, this is the first study to evaluate the impact of dupilumab on several blood parameters in patients receiving treatment for CRswNP. Further studies are needed to confirm our results and to understand the underlying immunological mechanisms | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a dupilumab |2 NLM | |
| 650 | 7 | |a 420K487FSG |2 NLM | |
| 650 | 7 | |a Immunoglobulin A |2 NLM | |
| 650 | 7 | |a Immunoglobulin E |2 NLM | |
| 650 | 7 | |a 37341-29-0 |2 NLM | |
| 650 | 7 | |a Immunoglobulin G |2 NLM | |
| 700 | 1 | |a Ciofalo, Andrea |e verfasserin |4 aut | |
| 700 | 1 | |a Cavaliere, Carlo |e verfasserin |4 aut | |
| 700 | 1 | |a Begvarfaj, Elona |e verfasserin |4 aut | |
| 700 | 1 | |a Cascone, Francesca |e verfasserin |4 aut | |
| 700 | 1 | |a Alfonzo, Giacomo |e verfasserin |4 aut | |
| 700 | 1 | |a Cadeddu, Rosalba |e verfasserin |4 aut | |
| 700 | 1 | |a Millarelli, Stefano |e verfasserin |4 aut | |
| 700 | 1 | |a Bellocchi, Gianluca |e verfasserin |4 aut | |
| 700 | 1 | |a Greco, Antonio |e verfasserin |4 aut | |
| 700 | 1 | |a de Vincentiis, Marco |e verfasserin |4 aut | |
| 700 | 1 | |a Masieri, Simonetta |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of immunology research |d 2014 |g 2023(2023) vom: 15., Seite 4027701 |w (DE-627)NLM237451581 |x 2314-7156 |7 nnns |
| 773 | 1 | 8 | |g volume:2023 |g year:2023 |g day:15 |g pages:4027701 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1155/2023/4027701 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 2023 |j 2023 |b 15 |h 4027701 | ||